deltatrials
Completed PHASE3 NCT00257530

Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis

Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients

Sponsor: Drugs for Neglected Diseases

Conditions Cutaneous Leishmaniasis
Interventions Imiquimod
Updated 5 times since 2017 Last updated: Jun 11, 2008 Started: Dec 31, 2005 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

A PHASE3 clinical study on Cutaneous Leishmaniasis, this trial is completed. The trial is conducted by Drugs for Neglected Diseases and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Drugs for Neglected Diseases
Data source: Drugs for Neglected Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cusco, Peru
  • • Lima, Peru